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Abstract
C. difficile infection (CDI) is rarely reported in cystic fibrosis (CF) patients despite frequent hospitalisations and
antibiotic usage. Conversely, the prevalence of CDI in inflammatory bowel disease (IBD) has received increased
attention. We investigated components of the IgG-specific humoral immune response to C. difficile toxins A and B in
patients with C. difficile-associated diarrhoea (CDAD), IBD patients with CDI, CF patients and healthy controls.
Serum anti-toxin IgG was determined by ELISA. Circulating antigen-activated B-cells were investigated using Alexa
Fluor 488-labelled toxin A and assessed by flow cytometry. Following induction of differentiation of memory B-cells,
toxin A- and B-specific antibody secreting cells (ASCs) were quantified using ELISpot. We present the first data
showing levels of serum anti-toxin A and B antibodies were significantly higher in patients with CF (without a history
of CDI) than in CDAD patients and were stably maintained over time. Notably, the CDAD patients were significantly
older than the CF patients. We also show that circulating toxin A-specific memory B-cells (IgD-negative) can be
detected in CDAD patients [0.92 (0.09–1.78)%], and were prominent (5.64%, 1.14%) in two CF patients who were
asymptomatic carriers of C. difficile. There was correlation between toxin A- and B-specific ASCs, with significantly
higher proportions of the latter seen. In some with CDAD, high serum antibody levels were seen to only one of the
two toxins. Mucosal secretion of toxin-specific IgG was detected in an additional group of IBD patients with no history
of CDI. We conclude that enhanced and stable humoral immune responses to toxins A and B may protect CF and
some IBD patients against CDI. The impaired ability to generate strong and/or sustained toxin-specific antibody and
memory B-cell responses may increase susceptibility of older patients to CDI and highlight the need to investigate
the role of immune senescence in future studies.
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Introduction
C. difficile infection is a significant clinical problem in patients
exposed to the hospital environment. Clinical presentation in
those colonised with toxigenic C. difficile can include
asymptomatic carriage, mild self-limiting diarrhoea and severe
life-threatening pseudomembranous colitis. Exposure to
antibiotics is the commonest risk factor, facilitating colonization
by C. difficile, via disruption of the protective resident microflora
[1,2,3].
Host factors that may determine the development and nature
of clinical disease are not fully understood but include age, the
use of proton-pump inhibitors or H2 blockers, tube feeding and
the host immune response [1,3,4,5,6]. Secreted toxins A and B
mediate the intestinal disease [1,7] and serum IgG antibodies
against toxin A appear to dominate protective responses in
humans; more recently, antitoxin B responses have been
correlated with colonization [3] and prevention of recurrent
disease [8]. There are also recent reports of an increase in
susceptibility to C. difficile infection in patients with
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inflammatory bowel disease [9]. By contrast, C. difficile-
associated disease is uncommon in patients with cystic
fibrosis, despite frequent admissions to hospital for antibiotics
for acute pulmonary exacerbations. Asymptomatic carriage of
C. difficile has been reported in 22-32% of such patients
[10,11], but the mechanism of protection against the
development of colonic disease remains to be determined.
The aim of our studies was to investigate, directly for the first
time, B lymphocyte anti-toxin A and anti-toxin B antibody
production as well as IgG-specific humoral immune responses
in patients with C. difficile-associated diarrhoea, C. difficile
infection in patients with inflammatory bowel disease and
patients with cystic fibrosis.
Materials & Methods
Subjects
Blood samples were obtained from adult healthy donors (19)
and patients attending two major hospitals in Nottingham, UK
between June 2009 and April 2012 (34 months). They
included: (i) 53 patients with C. difficile-associated diarrhoea,
(ii) 10 inflammatory bowel disease (7 ulcerative colitis, 3
Crohn’s disease) patients with C. difficile infection and (iii) 18
patients with cystic fibrosis. The diagnosis of cystic fibrosis had
previously been made on the basis of a positive sweat test
and/or demonstration of 2 known cystic fibrosis mutations and
typical clinical features of the disease. Intestinal mucosal
samples from an additional 15 patients with inflammatory bowel
disease (without a history of C. difficile infection) were also
studied.
Written informed consent, specific for each sample type
(blood, stool, mucosal tissue), was obtained before collection.
These studies were approved by the Nottingham Research
Ethics Committee, which also approved the consent procedure
for each sample type.
All the patients with C. difficile infection had diarrhoea
(defined as a change in bowel habit with 3 or more unformed
stools per day for at least 48 hours) and positive stool C.
difficile toxin test. Asymptomatic carriers were defined as those
without diarrhoea, but had a positive stool culture for C. difficile.
Sample collection
Serum was separated from venous blood samples and
aliquots stored at -800C, until use in ELISA assays. Peripheral
blood mononuclear cells (PBMCs) were isolated by
centrifugation of EDTA-treated venous blood samples over a
Ficoll-Hypaque (Sigma) density gradient. These cells were
subsequently used to study memory B cells and toxin A-
activated B cells. Frozen stool samples were treated and
cultured for C. difficile, as previously described [12]. Mucosal
samples were obtained from surgically-resected intestinal
tissue of patients with inflammatory bowel disease. Following
removal of epithelial cells, mucosal samples were cultured, as
previously described [13]. The presence of toxin-specific IgG
antibodies in supernatant samples was subsequently
investigated by ELISA.
Memory B cell stimulation assay
For induction of differentiation of memory B cells to antibody
secreting cells, the peripheral blood mononuclear cells were
cultured (0.5 x 106 cells/ml, at 370C, in 5% CO2) for 6 days in
RPMI (supplemented with 2 mM L-glutamine), 10% fetal calf
serum, 0.1 mg/ml penicillin G (Britannia Pharmaceuticals, UK),
0.1 mg/ml streptomycin (Sigma-Aldrich), and 0.1 mg/ml
gentamicin (Mayne Pharma Plc, UK), type B CpG
oligonucleotide (ODN 2006; 6 µg/ml; InvivoGen), recombinant
human interleukin (IL)-21 (Miltenyi Biotech) and recombinant
human CD40 ligand (Miltenyi Biotech). Following
centrifugation, aliquots of culture supernatant samples were
stored at -800C. After washing, the cells were used in ELISpot
assays.
Flow cytometry staining and analysis
Antigen-activated B cells were investigated using Alexa
Fluor® 488-labelled toxin A (toxin A488 [14]). Peripheral blood
mononuclear cells (2 x 106) were incubated on ice with 10
µg/ml toxin A488 on a rocker, in the dark, for 1 hour. After
washing, the cells were labelled with antibodies to CD19
(Beckman Coulter) and IgD (Southern Biotech). Washed cells
were fixed in 0.5ml of 0.5% formaldehyde and subsequently
studied by flow cytometry (FACScan FC500, Beckman-
Coulter). Data files of up to 1x106 events were collected for
each test sample and the resultant dot-plots were opened in
Weasel version 3 software (Walter and Eliza Hall Institute of
Medical Research) which was used to draw regions
encompassing toxin A488 positively labelled events.
ELISA
Toxin A- and toxin B-specific IgG responses in serum
samples were determined by ELISA. Flat-bottom 96-well ELISA
plates (F96 CERT Maxisorp NUNC, Thermo Scientific) were
coated with 100µl of a 30µg/ml solution of purified toxin A or B
in 0.05 M carbonate-bicarbonate buffer (pH 9.6) and incubated
overnight at 4°C. After washing six times with PBS-0.05%
Tween 20 using an automatic plate washer (ELx50 automated
strip washer; Biotek Instruments, Inc.), blocking solution
(PBS-0.05% Tween 20 containing 0.05% azide and 1% goat
serum) was added to each well and incubated for three hours
at 25°C. After further washing, sera diluted (1:100) in
PBS-0.05% Tween 20 containing 0.05% azide (or lamina
propria cell culture supernatant samples at 1:4 dilution) were
added to each well (100 µl) in triplicate and incubated for two
hours at 25°C. After washing, positive reactions were detected
by successive incubations with 100µl dilution of 5 µg/ml
biotinylated anti-human IgG (Vector) in PBS-0.05% Tween 20
containing 1% goat serum for one hour at 25°C and with a
streptavidin-horseradish peroxidase substrate (Vector) for 20
minutes at 25°C. The final reaction was visualized by the
addition of 2,2’-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid)
for 20 minutes in the dark. A405 values were measured in an
ELISA plate reader. The A405 values for the negative control
wells were averaged and subtracted from toxin-coated wells to
give the corrected A405 values for each test sample. ELISA
units (EU) in test sera were then calculated from their OD405
values using a standard curve established from serial dilutions
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(1:25 to 1:1600) of pooled serum samples with high anti-toxin
antibody titres. If the corrected OD405 value of a sample fell
below that of the lower plateau in the standard curve, it was
deemed negative and given an arbitrary value of 0.01 EU.
ELISpot
Ninety six-well ELISpot plates (Millipore Multiscreen
MSIPS4510 HTS IP Sterile plate 0.45 µm, hydrophobic, high-
protein binding) were pre-treated with 15 µl of 35% ethanol for
1 minute. After three washes with PBS the plates were
incubated overnight (at 4°C) with goat anti-human IgG Fc
fragment (10 µg/ml, from Bethyl Laboratories, to detect all IgG-
secreting cells) and either PBS (control), purified toxin A or
purified toxin B (both at a concentration of 30 µg/ml). After
washing 4 times with PBS, plates were blocked with 200µl/well
of RPMI-1640 supplemented with 10% FCS. To induce
differentiation of memory B cells to antibody secreting cells,
mitogen-stimulated peripheral blood mononuclear cells were
subsequently applied to ELISpot plates (25 x 103 cells/well to
detect total IgG ASCs or 2 x 105 cells/well to detect toxin-
specific ASCs). Control wells that were incorporated in each
plate included those with no cells (media only), and wells to
which unstimulated peripheral blood mononuclear cells were
added. Following incubation for 18 hours (at 37°C, 5% CO2),
the wells were washed 4 times with PBS, followed by
PBS-0.05% Tween 20. Diluted (1:1000 in PBS-0.05% Tween
20) horseradish peroxidise-conjugated goat anti-human IgG Fc
fragment antibodies (Jackson Immunoresearch) were added to
the wells and incubated overnight at 4°C. After removal of the
underdrain, plates were washed (3 times with PBS-0.05%
Tween 20 and 6 times with PBS) and developed with 3-
amino-9-ethylcarbazole (AEC) substrate (BD Biosciences). The
plates were washed thoroughly with distilled water and allowed
to dry overnight. Spot-forming cells were subsequently
enumerated in a blinded fashion using a dissection
microscope. The number of toxin A- and B-specific IgG ASCs
were expressed as a percentage of the total number of IgG
antibody secreting cells. For analysis, the number of
background spots from control wells (those containing
unstimulated cells or lacking capture antigen) were subtracted
from those coated with antigen.
Culture of intestinal mucosa samples
To investigate antibody secretion by intestinal lamina propria
cells, fresh mucosal samples (which were surplus to clinical
requirements) were obtained from surgically-resected intestinal
tissue of patients with ulcerative colitis or Crohn’s disease.
Following removal of epithelial cells with EDTA, small pieces of
mucosal samples were cultured in RPMI 1640 containing 10%
fetal calf serum, 2mM L-glutamine and antibiotics for 24 hours,
as previously described [13]. Supernatant samples were
subsequently collected (after centrifugation to remove lamina
propria cells) and stored at -800C, prior to use in ELISA.
Purification of C. difficile toxins
Toxins A and B were purified from supernatant samples of
anaerobically cultured C. difficile VPI strain 10463, as
previously described [15,16,17].
Statistical analysis
Groups of patients were compared using two-tailed non-
parametric tests (Spearman correlation, Kruskal-Wallis,
Table 1. Study subject characteristics and anti-toxin antibody responses.
 Healthy controls (n=19)
Patients with C. difficile-
associated diarrhoea (n=53)
IBD patients with C. difficile
infection (n=10)
Cystic fibrosis patients
(n=18)
Age (yrs) 30 (22-39) 71 (21-98)* 34.5 (21-83) 27.5 (19-49)
Male/female 10/9 22/31 4/6 10/8
Diabetes mellitus 0 7 0 16
Liver disease 0 3 0 5
PEG/NG feeding 0 2 0 5
Immunosuppressive treatment (corticosteroid/
other) 0 9/3 6/4 2/2
#
PPI / H2 blocker 0 31 4 14
Pancreatic enzyme supplements 0 0 1 17
Number of hospital admissions over study period 0 3 (1-25)a 1 (1-5)b 4.5 (1-10)
Serum anti-toxin A Igg (EU)§ 10.27 (0.01-59.51)c 17.74 (0.01-161.50)d 47.44 (0.01-182.40) 41.78 (1.62-159.4)†
Serum anti-toxin B Igg (EU)§ 16.08 (0.01-70.68)e 38.57 (0.01-97.97)f 26.37 (1.62-93.08) 62.7 (12.17-89.12)†
*. p<0.003 vs other groups
#. post liver / lung transplantation
§. if more than one serum sample was studied per subject, the mean antibody concentration was used for analysis
†. data from 16 patients with no history of C. difficile infection [mean values for the two patients with history of C. difficile infection: anti-toxin A: 109.5 (86.96-125.48) and
112.00 (84.55-129.71); anti-toxin B: 87.53 (68.34-96.95) and 61.31 (53.42-77.63)].
Comparison with cystic fibrosis group: ap<0.05, bp<0.01, cp=0.004, dp=0.02, e p = 0001, fp=0.0073
IBD = inflammatory bowel disease; PEG = percutaneous endoscopic gastrostomy; NG = nasogastric, PPI = proton pump inhibitor
doi: 10.1371/journal.pone.0074452.t001
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Wilcoxon matched-pairs signed rank and Mann Whitney tests)
and Fisher’s exact test. Data are expressed as median (range).
Multiple serum samples were studied from many patients.
Fluctuation in serum antibody concentrations in individual
subjects over time was assessed using coefficient of variation.
For comparative studies between groups, if more than one
serum antibody concentration was determined, mean anti-toxin
A and anti-toxin B antibody values were used per patient. A
significance level of ≤0.05 was considered statistically
significant.
Results
The characteristics of the subjects in the four study groups
are shown in Table 1, which also demonstrates that patients
with C. difficile-associated diarrhoea were significantly older
than those in the other three groups. In 16 of the 18 patients
with cystic fibrosis, there was no history of C. difficile infection;
2 had a history of previous C. difficile infection; stool samples
from a further 2 patients grew C. difficile and they were
therefore deemed to be carriers. During the study period,
patients in the cystic fibrosis group had significantly more
hospital admissions than those in the other two patient groups
(see table 1). At study enrolment, out of 18 of patients in the
cystic fibrosis group, 15 and 3 patients were on 2 and 3
concurrent intravenous antibiotics, respectively. The most
commonly prescribed antibiotics in descending order were
Meropenem, Tobramycin, Amikacin, and Ceftazidime. In the
inflammatory bowel disease group, 5 patients had no history of
antibiotic usage within the 6 weeks prior to C. difficile infection.
In the other 5 patients, two were on 2 types of intravenous
antibiotics and one patient was on 3 antibiotics (antibiotics
used included Co-amoxiclav, Gentamicin, Trimethoprim,
Meropenem and Piperacillin and Tazobactam). In patients with
C. difficile-associated diarrhoea, the most commonly
prescribed antibiotics in descending order were Co-amoxiclav,
Piperacillin and Tazobactam, Flucloxacillin, and Meropenem.
Serum IgG levels
The majority of serum samples from healthy controls had
detectable anti-toxin IgG to toxin A (73.7%) and toxin B
(78.9%). Concentrations of anti-toxin -A and -B IgG were
significantly higher in patients with cystic fibrosis (with no
previous history of C. difficile infection) than in healthy controls
and patients with C. difficile-associated diarrhoea (Table 1 and
Figure 1).
Compared with samples from the inflammatory bowel
disease patients (n = 22), a significantly greater proportion of
serum samples from the cystic fibrosis patients (n = 40) were
positive for anti-toxin A IgG (97.5% vs 77.3%, p=0.0183) and
anti-toxin B IgG (100% vs 77.3%, p=0.0041).
In paired comparisons, using all the samples collected, there
was no correlation between serum anti-toxin A and anti-toxin B
antibody levels in any of the patient groups.
Serum anti-toxin IgG concentrations over time
In those patients with C. difficile-associated diarrhoea from
whom 3 or more serum samples were obtained, serum anti-
toxin A IgG and anti-toxin B IgG were seen to fluctuate over
time. This is illustrated in Figure 2.
Within the patients with C. difficile associated diarrhoea, no
significant difference in serum anti-toxin IgG was seen between
those patients with single episode or recurrent disease (data
not shown). However, in a patient with 8 episodes of C. difficile-
associated diarrhoea either very low or undetectable anti-toxin
IgG levels were observed (Figure 2). This patient went on to
Figure 1.  Serum anti-toxin IgG.  Serum anti-toxin A (A) and anti-toxin B (A) IgG levels in healthy controls (n=19), patients with
cystic fibrosis (CF; with no previous history of C. difficile infection; n=16), patients with inflammatory bowel disease (IBD) and C.
difficile infection (n=10) and patients with C. difficile-associated diarrhoea (CDAD; n=53). If more than one serum sample was
studied per subject, the mean antibody concentration was used for the calculation. Anti-toxin A and B levels in patients with cystic
fibrosis were significantly higher than those observed in healthy controls and patients with C. difficile-associated diarrhoea.
doi: 10.1371/journal.pone.0074452.g001
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have treatment with intravenous pooled human immunoglobulin
and had no further recurrences during the subsequent 12
month follow-up period.
In those patients with cystic fibrosis, serum anti-toxin A and
anti-toxin B IgG concentrations remained largely stable over
time (Figure 3). A measure of stability over time was made by
calculating the coefficient of variation for IgG levels in those
patients with 3 or more samples. Significantly greater variation
in serum anti-toxin B IgG concentrations were seen in patients
with C. difficile-associated diarrhoea when compared with
patients with cystic fibrosis and is shown in Figure 4 [anti-toxin
A: 51.61% (0.0-173.0) vs 14.41% (6.31-67.42), p=0.074; anti-
toxin B: 55.37% (4.73-172.4) vs 13.82% (2.45-37.78),
p=0.017].
Circulating C. difficile toxin A-specific antigen activated
B cell responses
Peripheral blood mononuclear cells of cystic fibrosis patients
without a history of diarrhoea [n=4; median age 23 yrs (20-26
yrs)] and non-CF patients with C. difficile-associated diarrhoea
[n=20; median age 67 yrs (32-96 yrs), blood samples obtained
within 10 days of the onset of diarrhoea] were exposed to
fluorescently-labelled toxin A488 and labelled with antibodies to
CD19 (pan B cell marker) and IgD (expression lost in switched
memory B cells).
In patients with C. difficile-associated diarrhoea, a
significantly greater proportion of events were seen in the
CD19-positive, IgD-negative gate in PBMCS exposed to toxin
A488 [0.09% (0-0.54) versus 0.92% (0.09-1.78%); p<0.001
Wilcoxon matched-pairs], compared to control buffer. These
results suggest that a small proportion of toxin A-specific,
antigen-activated B cells can be detected in the peripheral
circulation of patients soon after C. difficile infection (table 2;
Figure 5). Compared to control buffer, a significantly greater
proportion of toxin A488-specific events were seen in the CD19-
positive/IgD-positive gates in patients with C. difficile
associated diarrhoea.
In the two cystic fibrosis patients who were asymptomatic
carries of C. difficile, >1% (up to 5.64%) of toxin A488-specific
events were seen in the above gates (table 2).
Figure 2.  Serum anti-toxin IgG over time in patients with C. difficile-associated diarrhoea.  (A, B) Serum anti-toxin A and B
IgG levels respectively in patients with a single episode of C. difficile infection. (C, D) Anti-toxin A and B IgG levels respectively in
patients with recurrent disease. The red line indicates a patient with 8 recurrences.
Data are for patients from whom three or more serum samples were obtained.
doi: 10.1371/journal.pone.0074452.g002
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Circulating memory B cell responses to C. difficile
toxins
Following mitogen-induced differentiation of memory B cells,
toxin A- and B-specific antibody secreting cells were
enumerated using ELISpot assays and expressed as a
percentage of total IgG-secreting cells.
In initial tests of polyclonal activation, the concentration of
human IgG secreted into PBMC cell culture supernatant
samples (34 samples from 19 patients) was significantly higher
following mitogen stimulation compared to cells cultured in
control medium [median 0.026 µg/ml (range 0.0-6.454) vs
0.465 µg/ml (0.001-7.172); p <0.0001). Anti-toxin A and B IgG
was detectable in 12% and 26.2% of supernatant samples of
mitogen-stimulated peripheral blood mononuclear cells,
respectively. Toxin A-specific (66.7%) and B-specific (100%)
antibody secreting cells were detected in their respective
ELISpot assays following polyclonal stimulation of peripheral
blood mononuclear cells.
Peripheral blood mononuclear cells were isolated from 39
blood samples, collected at varying time intervals after onset of
C. difficile-associated diarrhoea in 16 patients [samples
obtained at median 181 (range 81-415) days after the onset of
symptoms]. There was significant correlation (p=0.0035)
between the frequency of toxin A- and toxin B-specific antibody
secreting cells (Figure 6).
In the same samples, a significantly greater proportion of
toxin B-specific, than toxin A-specific memory B cells were
detected [0.82% (0 - 4.93) vs 0.33% (0 - 2.12); p<0.0001]
(Figure 7).
Similar findings were observed in samples obtained from four
patients with inflammatory bowel disease and C. difficile
infection and also in samples from patients with cystic fibrosis
(without a history of C. difficile infection) [0.67% (0 - 3.57) vs
0.20% (0 - 1.93); p=0.002] (Figure 8).
In circulating cells collected at 6 different time points from 2
patients with cystic fibrosis and a history of C. difficile infection,
there were significantly higher toxin A- and toxin B-specific
antibody secreting cells, compared to cells isolated from 13
cystic fibrosis patients with no previous history of C. difficile
infection [toxin A: 0.20% (0.0-1.93) vs 0.78% (0.06-6.67),
p=0.05; and toxin B: 0.675% (0.0-3.57) vs 3.315%
(0.32-11.67), p<0.03] (Figure 9). The highest proportion of toxin
Figure 3.  Serum anti-toxin IgG over time in patients with cystic fibrosis.  (A, B) Serum anti-toxin A and B IgG levels
respectively in patients without a history of C. difficile infection. (C, D) Anti-toxin A and B IgG levels respectively in patients with a
history of C. difficile infection.
Data are for patients from whom three or more serum samples were obtained.
doi: 10.1371/journal.pone.0074452.g003
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A-specific (6.67%) and toxin B-specific (11.67%) antibody
secreting cells was observed in one of the patients with cystic
fibrosis and a history of C. difficile infection, (sample obtained
121 days after the onset of C. difficile-associated diarrhoea).
Antibody and memory B cell responses to toxins A and
B in individual subjects
There was no correlation between serum anti-toxin IgG and
memory B cell frequencies in samples obtained from patients
with C. difficile-associated diarrhoea, inflammatory bowel
disease (with C. difficile infection) and those with cystic fibrosis.
Illustrative examples are shown in Figures 10 and 11. In
some patients in the C. difficile-associated diarrhoea and
inflammatory bowel disease (with C. difficile infection) groups,
serum IgG responses were not seen to either toxin A or B. In
the majority of the cystic fibrosis patients (17 of 18), serum
antibody responses were seen to both toxins.
In three patients (Figure 10 A, C, D) with C. difficile-
associated diarrhoea, serum anti-toxin IgG levels rose following
a second episode of infection and no further clinical recurrence
was observed.
Secretion of anti-toxin IgG by intestinal lamina propria
cells
In a group of patients with inflammatory bowel disease and
no history of C. difficile infection, secretion of toxin-specific IgG
antibodies by intestinal lamina propria cells was studied in
supernatant samples of cultured pieces of small and large
intestinal mucosa obtained from operation resection
specimens.
Supernatant samples were diluted 1:4 and ELISA Units (EU)
determined from OD405 values using a standard curve
established from serial dilutions of pooled serum samples with
high anti-toxin antibody titres.
In 2 (of 5) supernatant samples of mucosal tissue from
patients with ulcerative colitis and 3 (of 8) with colonic Crohn’s
disease, anti-toxin B IgG was detected, but anti-toxin A IgG
was undetectable in all.
Table 2. Toxin A-specific antigen-activated B cell
frequencies by flow cytometry.
 
Control
CD19+ve/
IgD-ve
events (%)
Tox A488
CD19+ve/IgD-
ve events (%)
Control
CD19+ve/IgD
+ve events
(%)
Tox A488
CD19+ve/IgD
+ve events
(%)
Patients with C.
difficile- associated
diarrhoea (n=18) †
0.10 (0 -
0.54)
0.91*
(0.21-1.78)
0.07
(0.01-0.9)
0.90*
(0.02-2.60)
IBD patients with C.
difficile infection
(n=2)†
0, 0 1.26, 0.09 0.18, 0.21 1.24, 0.54
Cystic fibrosis
patients,
asymptomatic
carriers of C. difficile
(n=2)
0.08, 0 5.64, 1.14 0.04, 0.04 3.70, 1.42
Cystic fibrosis
patients, stool
negative for C.
difficile (n=2)
0.08, 0.07 0.95, 0.45 0.06, 0.10 1.33, 0.86
*. p<0.0005, vs relevant control
†Peripheral blood mononuclear cells were studied within 10 days of onset of
diarrhoea.
doi: 10.1371/journal.pone.0074452.t002
Figure 4.  Stability of toxin-specific antibody responses over time.  Coefficient of variation of (A) serum anti-toxin A and (B)
anti-toxin B antibody concentrations in patients with non-IBD CDAD and cystic fibrosis (subjects with 3 or more serum antibody
values). There is greater stability (ie less fluctuation) in toxin-specific antibody levels in patients with cystic fibrosis than those with
non-IBD CDAD; this reaches statistical significance for anti-toxin B (p=0.017), but not anti-toxin A (p=0.074).
doi: 10.1371/journal.pone.0074452.g004
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In cultures of 7 samples of small intestine from patients with
Crohn’s disease, anti-toxin A and anti-toxin B IgG were
detected in 2 and 7 respectively.
Anti-toxin A and B IgG antibodies were detected in
supernatant samples of cultured inflamed colonic mucosa from
a patient with C. difficile-associated pseudomembranous colitis
undergoing colectomy.
Discussion
Following initial exposure to a pathogen or its products,
protection by the humoral immune system is mediated by long-
lived plasma cell-derived antibodies and long-lived memory B
cells [18]. Our studies have investigated both types of IgG-
mediated humoral immune responses to C. difficile toxins in
patients with C. difficile-associated diarrhoea, IBD patients with
C. difficile infection and cystic fibrosis patients, the majority of
which had no previous history of C. difficile infection. Serum
anti-toxin IgG was also quantified in a separate groups of
healthy subjects.
Consistent with previous studies [19,20], the majority of the
healthy controls in our studies had detectable anti-toxin A and
anti-toxin B antibodies in their serum samples. This implies that
asymptomatic exposure to toxigenic C. difficile is common and
may be due to transient colonisation. Notably, significantly
higher anti-toxin antibody concentrations in patients with cystic
fibrosis (with no previous history of C. difficile infection) are
likely to be due to more frequent contact with the toxins
secreted by C. difficile that colonises the large intestine
following antibiotic-mediated disruption of the protective
resident microflora, especially following admission to hospital
[21]. Indeed, in contrast to patients with inflammatory bowel
disease, all the cystic fibrosis patients were on 2 or 3
intravenous antibiotics at the time of recruitment to the study.
The cystic fibrosis patients also had additional risk factors for
Figure 5.  Circulating C. difficile toxin A-specific, antigen activated B cells.  (A) Dot plots of CD19-positive peripheral blood
mononuclear cells isolated (within 10 days of onset of symptoms) from a patient with C. difficile infection and incubated with either
control buffer or toxin A488. IgD-negative and IgD-positive B cells that bound toxin A488 are represented by events in the right lower
and upper quadrants, respectively. (B, C) Toxin A488 labelled events as a percentage of CD19-positive/IgD-negative (B) and CD19-
positive/IgD-positive (C) events in patients with C. difficile-associated diarrhoea. When compared with control buffer, a significantly
greater proportion of events were seen in both the CD19-positive/IgD-negative and CD19-positive/IgD-positive gates in peripheral
blood mononuclear cells exposed to toxin A488.
doi: 10.1371/journal.pone.0074452.g005
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C. difficile colonization/infection including tube feeding, the use
of proton pump inhibitors and H2 blockers [3,4]. Frequent
exposure to the toxins may also explain maintenance of steady
serum anti-toxin antibody concentrations in patients with cystic
fibrosis. These circulating antibodies to toxins A and B are
believed to provide protection against the development of
disease [3,5,6,20], which may be best illustrated in the two
Figure 6.  Correlation of toxin A- and B-specific ASC
frequencies in patients with C. difficile-associated
diarrhoea.  Peripheral blood mononuclear cells from 39 blood
samples, collected at varying time intervals after onset of C.
difficile-associated diarrhoea in 16 patients (median 181 days
after onset of diarrhoea, range 81-415). There was significant
correlation (p=0.0035) between the frequency of toxin A- and
toxin B-specific IgG secreting cells (as percentage of total IgG-
secreting antibody secretory cells).
doi: 10.1371/journal.pone.0074452.g006
Figure 7.  Toxin A and B-specific ASC frequencies in
patients with C. difficile-associated diarrhoea.  Peripheral
blood mononuclear cells from 39 blood samples, collected at
varying time intervals after onset of C. difficile-associated
diarrhoea in 16 patients. A significantly higher proportion of
toxin B-specific antibody secretory cells (than toxin A-specific
antibody secretory cells) was detected [0.82 (0 - 4.93) % vs
0.33 (0 - 2.12) %; p<0.0001].
doi: 10.1371/journal.pone.0074452.g007
Figure 8.  Toxin A and B-specific ASC frequencies in patients with cystic fibrosis.  Peripheral blood mononuclear cells from
24 blood samples, collected at varying time intervals, from 13 patients with cystic fibrosis (with no previous history of C. difficile
infection) [samples obtained over median 161.5 (range 42-244) days]. There was significant correlation (p=0.0017) between toxin A-
and toxin B-specific IgG antibody secreting cells (A) with significantly higher proportions of the latter [0.67 (0 - 3.57) %) vs 0.20 (0 -
1.93) %; p=0.002] (B).
doi: 10.1371/journal.pone.0074452.g008
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asymptomatic carriers of toxigenic C. difficile. The development
of C. difficile infection in two cystic fibrosis patients suggest that
immune-mediated protection can be overcome and may reflect
tilting of the balance in favour of the pathogen. Such
“imbalance” may occur due to increased production of toxins A
and B, for example following infection with the NAP1 strain
[22], which has recently been reported to be associated more
frequently with C. difficile infection (than colonization) [3]. High
luminal concentrations of the toxins may overcome IgG and
other (IgA, mucus) forms of protection, leading to enhanced
susceptibility of host intestinal epithelial and lamina propria
cells [15,23]. Whilst firm conclusions cannot be drawn because
of the small number of subjects studied, cystic fibrosis patients
with previous C. difficile infection appeared to have an
enhanced memory B cell response and serum anti-toxin
antibody levels above the mean for the rest of the group. Such
heightened response may protect against recurrence.
Serum anti-toxin A and anti-toxin B antibody concentrations
in patients with C. difficile-associated diarrhoea were
significantly lower than in cystic fibrosis patients. Patients in the
former group were also significantly older, which may explain
the inability of these patients to mount as strong a humoral
immune response as those younger patients with cystic
fibrosis. Since many patients with C. difficile infection had
fluctuating anti-toxin antibody levels, our studies raise the
possibility that C. difficile toxin-specific long-lived plasma cell
numbers and/or function may not be sustained over time. This
could be a general feature of humoral immune responses to
bacterial toxins as, in contrast to viral antigens, antibody
responses to tetanus and diphtheria toxins have been reported
to wane more quickly [24]. Moreover, studies of the aged
human immune response (termed ‘immune senescence’)
document qualitative and quantitative decline in T and B
lymphocyte responses to a range of microbes and antigens.
Such changes could be due in part to impaired T cell help for B
cell IgG production, diminishing lymphocyte clonal repertoire
diversity (polyclonal to oligoclonal) and microenvironmental
factors in lymphoid tissue and bone marrow [25,26]. Such
information is relevant in efforts to induce and sustain
protective immunity against C. difficile infection via improved
vaccination strategies.
Whilst concentrations of serum IgG antibodies to toxin A and
toxin B did not differ between cystic fibrosis and inflammatory
bowel disease patients, greater heterogeneity in antibody
levels was seen in the latter group, as illustrated by the
absence of detectable antibody in some serum samples.
Significantly fewer hospital admissions in the inflammatory
bowel disease group suggest that such heterogeneity could be
due to less frequent exposure to C. difficile in the hospital
environment. Further studies with larger groups of patients are
required to determine whether patients with inflammatory bowel
disease are at greater risk of C. difficile infection than those
with cystic fibrosis. Of note, patients with long-standing
diagnoses of ulcerative colitis and Crohn’s disease in clinical
remission without recent exposure to antibiotics,
immunomodulatory drugs or recent hospitalisation,
demonstrate an increased frequency of detectable faecal C.
difficile when compared with healthy adults [27]. However, it
remains to be seen whether carriage of this bacterium in such
patients ultimately translates into increased risk of relapse and
will require larger numbers of subjects and longer-term follow-
up. Further studies are also required to determine the impact of
known risk factors for C. difficile acquisition including antibiotics
and immunomodulatory drugs in relation to carriage rates in the
IBD population [27].
Our studies in which cultures of some intestinal mucosal
samples affected by inflammatory bowel disease secreted
antibodies to C. difficile toxins suggest that exposure to
Figure 9.  Toxin A- and B-specific ASCs in patients with cystic fibrosis with and without previous C. difficile.  Peripheral
blood mononuclear cells were isolated from a total of 6 and 24 samples collected at varying time intervals from patients with cystic
fibrosis with (n=2) and without (n=13) previous history of C. difficile infection, respectively. The frequencies of toxin A- and B-specific
antibody secreting cells were significantly higher in those patients with previous C. difficile infection than those without. (A) toxin A-
specific ASCs (p=0.05); (B) toxin B-specific ASCs (p=0.026).
doi: 10.1371/journal.pone.0074452.g009
Humoral Immune Responses in C. difficile Infection
PLOS ONE | www.plosone.org 10 September 2013 | Volume 8 | Issue 9 | e74452
Figure 10.  Toxin-specific antibody and memory B cell responses in non-IBD and IBD patients.  Case studies (A–F) showing
toxin A- and toxin B-specific serum antibody levels and memory ASC frequencies in non-IBD CDAD and IBD-CDAD patients. (A) 67
yr female, 1st sample 5d after onset of diarrhoea associated with 1st episode of C. difficile infection. Recurrence of infection after
26d (dashed arrow) with no further episodes over 21mths. (B) 62 yr female, 1st sample 7d after 2nd episode of C. difficile infection
(solid arrow). No recurrences over 14mths. (C) 71 yr female, 1st sample 12d after onset of diarrhoea associated with 1st episode of
severe C. difficile infection (solid arrow). Second episode of infection (dashed arrow) after 94d but no further episodes over
subsequent 15mths. (D) 62 yr female, 1st sample 7d after onset of diarrhoea associated with 1st episode of severe C. difficile
infection (solid arrow). Recurrence at 30d (dashed arrow). No further episodes of infection over subsequent 13mths. (E) 32 yr
pregnant female, recent diagnosis of ulcerative colitis. Hospital admission for intravenous corticosteroids 17d prior to 1st sample.
Two initial stool samples negative for C. difficile toxin. Four days before first blood sample, positive stool C. difficile toxin test (solid
arrow). (F) 28 yr female with ulcerative colitis and recurrent C. difficile infection. First sample during 3rd episode of C. difficile
infection (1st episode occurred 60d previously – solid arrow). Fourth episode of C. difficile infection (dashed arrow) at 135d. In
intervening period, patient was taking corticosteroids, ciclosporin and azathioprine.
doi: 10.1371/journal.pone.0074452.g010
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Figure 11.  Toxin-specific antibody and memory B cell responses in cystic fibrosis patients.  Case studies (A–F) showing
toxin A- and toxin B-specific serum antibody levels and memory ASC frequencies in patients with cystic fibrosis. (A) 26 yr male with
insulin-dependent diabetes mellitus, previous fundoplication and gastrostomy. Colonised with C. difficile at recruitment. No history of
diarrhoea during study period and subsequent 17mths. (B) 24 yr male with insulin-dependent diabetes mellitus. Colonised with C.
difficile at recruitment. (C) 32 yr male with insulin-dependent diabetes mellitus. Not colonised with C. difficile at recruitment. No
history of diarrhoea during the study or follow-up period. (D) 24 yr male with insulin-dependent diabetes mellitus, previous bilateral
lung transplantation 3d after first sample. Subsequently taking prednisolone, azathioprine, tacrolimus and cotrimoxazole. (E) 34 yr
female with insulin-dependent diabetes mellitus. Overnight feeding via jejunostomy. C. difficile infection with diarrhoea 10mths prior
to first sample. No recurrence of C. difficile infection during the study or subsequent 9 month follow-up period. (F) 28 yr male
recruited during episode of clinical C. difficile associated diarrhoea. No recurrence of C. difficile infection during the study period or
14mth follow-up period.
doi: 10.1371/journal.pone.0074452.g011
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toxigenic C. difficile is not uncommon in such patients. These
patients were not thought to have had clinical C. difficile
infection, implying asymptomatic exposure to toxigenic C.
difficile, with protection mediated by anti-toxin antibodies
secreted by plasma cells in the mucosa. It will also be of
interest to determine whether the antibody producing cells in
the mucosa of patients with inflammatory bowel disease
represent long-lived plasma cells.
Impaired mucosal regulatory T cell function has been
implicated in the pathogenesis of inflammatory bowel disease
[28] but the effect of C. difficile infection on T cell function in
patients with ulcerative colitis and Crohn’s disease remains to
be determined. It is possible that C. difficile toxin-induced
cytokine expression in macrophages [29] may lead to
resistance of effector T cells to suppression by regulatory T
cells and thereby lead to exacerbation of mucosal inflammation
in inflammatory bowel disease. Changes in the resident
microbial flora associated with C. difficile infection may also
adversely influence mucosal regulatory T cells function.
In peripheral blood mononuclear cells, following
differentiation of memory B cells, there was significant
correlation between toxin A- and toxin B-specific antibody
secreting cells (with greater proportions of the latter). However,
there was lack of correlation between toxin A- or toxin B-
specific serum antibody levels and the relevant memory B cell
responses. Such lack of correlation between serum antibody
concentrations (derived from long-lived plasma cells) and
circulating memory B cell numbers has also been reported for
other antigens [24] and likely reflects independent regulation of
the development of the relevant cells in germinal centres [18].
The findings of toxin A488+ve CD19-positive/IgD-negative
and CD19-positive/IgD-positive cells are consistent with the
presence of switched (IgD-negative) and unswitched (IgD-
positive), toxin A-specific memory B cells. They also reflect
heterogeneity in the generation of memory B cell populations
[30]. However, the functional contributions of these distinct
subpopulations of cells in host protection remains to be
determined. More detailed phenotypic studies aimed at
characterising human memory B cell subsets in patients with C.
difficile infection may help identify B cell signatures associated
with disease severity, prognosis and response to treatment.
In conclusion, our studies provide further evidence for the
importance of the humoral immune response to toxins A and B
in protection against C. difficile infection. The impaired ability to
generate strong and sustained toxin-specific humoral immune
responses, via long-lived plasma cells and long-lived memory
B cells, may increase susceptibility of older individuals to C.
difficile infection and warrants further investigation of the role of
immune senescence.
Overall, our data suggest that serum anti-toxin antibodies
may underestimate the breadth of humoral immunity in relation
to C. difficile infection and strongly support the use of toxin-
specific B memory cell analyses to complement serological
studies. The antigen-specific flow cytometric and ELISpot
techniques described in this report could find utility in the
development of an effective novel vaccine against C. difficile
infection that induces long-lived protection.
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